OE19 Cells
USD$375.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | OE19 is a human oesophageal adenocarcinoma cell line derived from the primary tumor of a patient with Barrett’s oesophagus-associated adenocarcinoma. This cell line is widely utilized in research focused on oesophageal cancers, particularly for investigating tumorigenesis in the context of Barrett’s oesophagus progression. OE19 serves as a model to study the molecular mechanisms underlying adenocarcinoma development, therapeutic responses, and resistance mechanisms in upper gastrointestinal malignancies. OE19 cells exhibit an epithelial morphology and adhere under standard culture conditions. They are characterized by genomic alterations and molecular features typical of oesophageal adenocarcinoma, including overexpression of HER2/neu (ERBB2), a hallmark of aggressive tumor behavior and a clinically significant target for therapy. This makes OE19 particularly relevant for testing HER2-targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors. Additionally, OE19 cells are used to explore signaling pathways critical to cancer progression, including MAPK/ERK and PI3K/AKT pathways, as well as mechanisms of immune evasion and interaction with the tumor microenvironment. In preclinical studies, OE19 is valuable for evaluating chemotherapeutic agents, targeted therapies, and novel combinations aimed at overcoming drug resistance. The cell line is also employed in xenograft models to assess tumor growth and therapeutic efficacy in vivo. Its molecular profile and relevance to Barrett’s oesophagus-related adenocarcinoma make OE19 a significant resource for advancing the understanding and treatment of this challenging malignancy. |
|---|---|
| Organism | Human |
| Tissue | Esophagus |
| Disease | Adenocarcinoma |
| Synonyms | OE-19, JROECL 19, JROECL19, OEC19 |
Characteristics
| Age | 72 years |
|---|---|
| Gender | Male |
| Ethnicity | European |
| Morphology | Epithelial-like |
| Growth properties | Adherent |
Regulatory Data
| Citation | OE19 (Cytion catalog number 305441) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1622 |
Biomolecular Data
| Mutational profile | Mutation: TP53, Simple, p.Asn310Lysfs*27 (c.929dup) (c.929_930ins1), Heterozygous |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase 10 min 37°C |
| Doubling time | 50-60 hours |
| Seeding density | 2 to 5 x 104 cells/cm2 |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305441-260226 | Certificate of Analysis | 26. Mar. 2026 | 305441 |